Brief Summary:The post-Covid syndrome is a problem that affects a significant number of people in theworld. Among the most common symptoms is pain, and although there is no specific data onneuropathic pain and Covid, due to under-diagnosis, they may be closely related.Non-invasive neuromodulation acts on the Central Nervous System through the bioelectricalstimulation of nervous tissue and modulation of the system nervous, and can be useful inacute, chronic and musculosqueletal pain, and in symptoms such as stress, anxiety andsleep disturbances.The objective of this clinical trial is to assess the efficacy of non-invasiveneuromodulation in the treatment of post-Covid musculoskeletal pain. Subjects will berandomly divided into two groups: an experimental group in which non-invasiveneuromodulation will be applied and a sham group to which it will be applied off. Thevariables to be studied before, during and after treatment will be neuropathic pain withthe DN4 questionnaire, pain intensity with the EVA scale, sleep quality with thePittsburgh Sleep Quality Index, level of stress and anxiety with the HADS questionnaireand quality of life with the SF12.